These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28654428)

  • 1. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients.
    Cheng E; Ko D; Nguyen M; Moo TA; Andreopoulou E; Hoda SA; D'Alfonso TM
    Am J Surg Pathol; 2017 Sep; 41(9):1275-1282. PubMed ID: 28654428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: Not pathologic complete response.
    Lee H; Jang Y; Cho YA; Cho EY
    Hum Pathol; 2024 Mar; 145():1-8. PubMed ID: 38311186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
    Rabban JT; Glidden D; Kwan ML; Chen YY
    Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy.
    Morohashi S; Yoshizawa T; Seino H; Hirai H; Haga T; Ota R; Wu Y; Yoshida E; Hakamada K; Kijima H
    Oncol Rep; 2016 May; 35(5):2592-8. PubMed ID: 26935647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pure Intralymphatic Invasion in the Absence of Stromal Invasion After Neoadjuvant Therapy: A Rare Pattern of Residual Breast Carcinoma.
    Guilbert MC; Overmoyer B; Lester SC
    Am J Surg Pathol; 2018 May; 42(5):679-686. PubMed ID: 29394169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of breast MRI with regard to axillary reverse mapping in clinically node positive breast cancer patients following neo-adjuvant chemotherapy.
    Beek MA; Tetteroo E; Luiten EJ; Gobardhan PD; Rutten HJ; Heijns JB; Voogd AC; Klompenhouwer EG
    Eur J Surg Oncol; 2016 May; 42(5):672-8. PubMed ID: 26898838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
    Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
    Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postneoadjuvant Pure and Predominantly Pure Intralymphatic Breast Carcinoma: Case Series and Literature Review.
    MacColl CE; Paré G; Salehi A; Hodgson N; Williams P
    Am J Surg Pathol; 2021 Apr; 45(4):537-542. PubMed ID: 33105157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
    Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
    PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
    Javid S; Segara D; Lotfi P; Raza S; Golshan M
    Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
    Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
    Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer].
    Tokita H; Aruga T; Yamashita T; Saji S; Suzuki E; Horiguchi K; Kitagawa D; Sekine S; Horiguchi S; Hirashima Y; Kuroi K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1639-45. PubMed ID: 21996959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
    Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
    Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
    Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
    J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.